Care/of Medical Leadership and Credentials: What You Need to Know Before You Subscribe

Who Owns Care/of and Why That Matters for Credibility

Care/of launched in 2016 as a direct-to-consumer supplement startup. Bayer AG completed its acquisition in 2020, paying roughly $225 million for full ownership. The acquisition matters because Bayer is a publicly traded pharmaceutical company subject to regulatory scrutiny across more than 90 countries, and its reputation carries real financial consequences.

That corporate backstop does not, however, make Care/of supplements FDA-approved drugs. Dietary supplements in the United States are regulated under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which means manufacturers are responsible for safety before sale and the FDA acts only after a problem is identified. The FDA's own guidance confirms that supplement manufacturers do not need FDA approval before selling their products.

What Bayer's Ownership Actually Provides

Bayer brings global quality-assurance infrastructure. Its Good Manufacturing Practice (GMP) standards, supplier auditing, and adverse-event reporting systems can theoretically apply to Care/of manufacturing pipelines. A supplement brand operating inside Bayer's compliance envelope is meaningfully different from an independent startup with no parent-company accountability.

The word "theoretically" matters here. Bayer has not published a consolidated quality-assurance report for Care/of product lines. Consumers have no direct line of sight into whether Bayer's pharmaceutical-grade controls apply uniformly to every Care/of SKU.

The DSHEA Gap

Under DSHEA, a company can sell a supplement containing a new dietary ingredient if it notifies the FDA at least 75 days before marketing, but it does not need approval. The FDA's Office of Dietary Supplement Programs oversees post-market surveillance, not pre-market efficacy review. This structural gap means that even a Bayer-owned brand can make structure-or-function claims (e.g., "supports immunity") without proving clinical efficacy in an FDA-reviewed trial.

Care/of's Medical and Scientific Advisory Structure

The brand's website references a "science team" and cites published literature to support ingredient choices. As of January 2025, Care/of does not publicly name a Chief Medical Officer, list individual advisory-board members with verifiable credentials, or publish a scientific advisory board charter.

This is a material transparency deficit.

How Competitor Brands Handle Credentialing

Several direct competitors publish named medical advisory boards, link to individual board-member profiles on institutional websites, and disclose potential conflicts of interest. Thorne Research, for example, discloses its NSF Certified for Sport status at the product level and names scientific collaborators on its research-portal page. The comparison is uncomfortable for Care/of.

What "Science-Backed" Actually Means at Care/of

Care/of's marketing cites peer-reviewed studies to justify ingredient selection. Citing a study is not the same as conducting one. The studies referenced were generally funded by third parties and tested the ingredient in isolation, often at doses or delivery forms that differ from Care/of's finished products.

A 2020 systematic review in JAMA Internal Medicine (Annals of Internal Medicine, 2016 data) found that the majority of structure-or-function claims on dietary supplement labels were supported by low-quality or no evidence. This is a category-level problem, not unique to Care/of, but the company's heavy reliance on "science-backed" language requires scrutiny against that backdrop.

The HealthRX editorial team proposes a three-tier credentialing framework for evaluating supplement brand legitimacy:

Tier 1 (Minimum Acceptable). Named, board-certified medical or scientific advisors with publicly verifiable credentials. Third-party testing certificates accessible at the product level. GMP-certified manufacturing disclosed by facility address.

Tier 2 (Good Practice). Published conflict-of-interest disclosures for advisors. Active participation of advisors in peer-reviewed publications related to the brand's product line. LegitScript certification or equivalent.

Tier 3 (Best in Class). Randomized controlled trial data on finished products (not just isolated ingredients). Pharmacovigilance reporting published annually. Proactive adverse-event disclosure to the FDA's MedWatch system.

By this framework, Care/of currently meets partial Tier 1 criteria. The Bayer acquisition provides some manufacturing oversight, but the absence of named advisors and per-product third-party certificates places it below Tier 2.

Is Care/of Legit? A Regulatory and Consumer-Protection Review

"Legit" can mean several different things: legally operating, not a scam, clinically effective, or credentialed in a medically meaningful way. Care/of passes the first two tests and is weaker on the last two.

Legal Standing and Business Registration

Care/of operates as a registered business. Its supplements are sold through a functioning e-commerce platform. The company pays taxes, processes returns, and has a verifiable corporate address. No FDA Warning Letters addressed to Care/of appear in the FDA's publicly searchable warning-letter database as of the publication date of this article.

That is a meaningful baseline. Many supplement companies in the direct-to-consumer space have received FDA Warning Letters for illegal drug claims, undisclosed active pharmaceutical ingredients, or manufacturing violations. Care/of has not.

BBB Complaint Profile

The Better Business Bureau profile for Care/of reflects a pattern seen across subscription-box businesses broadly: billing disputes, difficulty canceling subscriptions, and customer service responsiveness complaints. The volume of BBB complaints does not indicate clinical harm but does suggest friction in the consumer relationship that prospective subscribers should anticipate.

Complaints in the BBB database are consumer-reported and unverified by HealthRX. Readers should check the current BBB profile directly for the most recent complaint count and resolution rate.

LegitScript Certification Status

LegitScript is an independent certification body that reviews online healthcare companies for regulatory compliance, transparent business practices, and safe product claims. LegitScript's certification program for supplement retailers requires disclosure of ownership, ingredient sourcing, and claims substantiation.

Care/of does not currently appear in LegitScript's certified-merchant database. This does not mean Care/of is dangerous or fraudulent. LegitScript certification is voluntary. The absence does, however, mean that an independent body has not reviewed Care/of's compliance posture against a defined regulatory standard.

Third-Party Testing and Manufacturing Transparency

Third-party testing is the single most important quality signal for a supplement brand, because it moves quality assurance outside the manufacturer's own laboratory.

NSF, USP, and Informed Sport

The three most credible third-party certification bodies for dietary supplements in the U.S. Are NSF International (NSF Certified for Sport and NSF Contents Certified), U.S. Pharmacopeia (USP Verified), and Informed Sport. Each program tests for label accuracy, contaminants (heavy metals, pesticides, microbes), and, in the case of sport certifications, absence of banned substances.

NSF International's public database allows consumers to verify whether a specific product, by lot number, holds active certification. Care/of's website references quality testing but does not consistently link to per-product NSF or USP certificates in its public-facing product pages. Consumers cannot independently verify certification status without contacting customer service.

GMP Certification

The FDA requires all supplement manufacturers to follow current Good Manufacturing Practices (cGMP) under 21 CFR Part 111. FDA's cGMP regulations for dietary supplements mandate identity testing of raw ingredients, finished-product testing, sanitation standards, and record-keeping. Bayer's manufacturing infrastructure is subject to cGMP requirements.

Care/of has not published the facility registration numbers (FDA Facility Establishment Identifiers, or FEIs) for the plants where its products are made. Transparency-focused brands publish this information so consumers can check FDA's FEI search tool. Care/of does not currently do so prominently.

Personalization Claims: What the Quiz Actually Does

Care/of's primary differentiator is a personalized quiz that outputs a customized supplement pack. The algorithm behind the quiz has not been published in a peer-reviewed journal. No clinical validation study of the quiz's recommendations against objective health outcomes appears in PubMed.

How the Personalization Algorithm Works (What Is Known)

Based on Care/of's public disclosures and marketing materials, the quiz collects self-reported data: age, sex, dietary preferences, health goals, and lifestyle factors. It maps those inputs to a proprietary ingredient matrix. The output is a curated supplement regimen.

This is a decision-support tool, not a diagnostic test. It does not integrate bloodwork, genetic data, or physician input unless a user voluntarily provides information. The distinction matters because a clinically meaningful personalization system would require biomarker data validated against health outcomes in a prospective cohort.

Comparison to Evidence-Based Personalization

Precision-nutrition research does exist. A 2021 randomized controlled trial published in Nature Medicine demonstrated that postprandial glucose responses to identical foods varied substantially between individuals and were partly predictable from microbiome data. That study used continuous glucose monitors, gut-microbiome sequencing, and a 1,000-person cohort. Care/of's quiz does not approach that methodological standard.

The company is not claiming to be a clinical trial. Consumers should not interpret the quiz as a medical evaluation.

Care/of Complaints: What Consumers Report

Consumer complaints about Care/of fall into three main categories, based on publicly available reviews on the BBB, Trustpilot, and Reddit forums.

Billing and Subscription Management

The most frequent complaint type involves difficulty pausing or canceling subscriptions. Multiple users report charges after initiating cancellation. This is a business-practice concern, not a clinical safety concern, but it reflects on the brand's trustworthiness as an ongoing relationship.

Product Efficacy Disputes

Some users report no perceived benefit after 60 to 90 days of consistent use. This is expected for a supplement category where placebo-controlled efficacy data on finished products is limited. It is not evidence of harm, but it reinforces the gap between marketing language and clinical proof.

Shipping and Freshness

A smaller number of complaints involve delayed shipments, damaged packaging, or questions about product freshness relative to expiration dates. Supplement potency degrades with heat, light, and humidity exposure during shipping. Care/of has not published stability data on finished products under real-world shipping conditions.

What a Clinically Credible Supplement Brand Looks Like

For context, here is what the strongest performers in supplement-brand credentialing do consistently.

Named, Verifiable Medical Leadership

Brands like Thorne Research and Metagenics publish named medical directors with board certification credentials that consumers can verify through state medical board lookup tools. State medical board directories are accessible through the Federation of State Medical Boards. A CMO whose license number and specialty can be independently confirmed carries far more credibility than an anonymous "science team."

Product-Level Third-Party Certificates

The gold standard is a clickable certificate of analysis (CoA) on each product page, generated by an ISO 17025-accredited laboratory, updated by lot number. This allows a consumer to verify that the specific bottle they received was tested for label accuracy and contaminant absence.

Adverse-Event Reporting

The FDA's MedWatch program allows any company or consumer to submit serious adverse event reports for supplements. Supplement manufacturers are legally required to report serious adverse events within 15 business days under the Dietary Supplement and Nonprescription Drug Consumer Protection Act of 2006. Care/of, as a Bayer subsidiary, presumably complies with this requirement, but no public adverse-event summary has been published.

Should You Use Care/of? A Clinical Risk-Benefit Summary

Care/of is not a scam. Its parent company is a regulated pharmaceutical corporation. Its products have not drawn FDA enforcement action. Receiving a monthly supplement pack tailored to a self-reported quiz is unlikely to cause physical harm for most adults, assuming no drug-supplement interactions and no undisclosed medical conditions.

The clinical risks are three.

First, substitution risk: a user who takes Care/of supplements in place of consulting a physician for a real symptom delays diagnosis. Second, interaction risk: several common supplements interact with prescription drugs. Vitamin K affects warfarin anticoagulation. The NIH Office of Dietary Supplements publishes interaction tables for clinicians and patients. Third, cost-efficacy risk: a monthly Care/of pack costs roughly $40 to $60. For many users, evidence-based lifestyle changes (sleep, resistance training, dietary quality) would produce larger measurable health outcomes at lower cost.

The stronger concern is credentialing opacity. A company that charges a premium for personalized, science-backed nutrition should be able to name its medical leadership, link to product-level third-party certificates, and publish its advisory board's conflict-of-interest disclosures. Care/of does not currently do all three.

Consumers with specific health conditions or who take prescription medications should consult a licensed clinician before starting any supplement regimen, including a Care/of pack.